Home Cancer Genetics and Molecular Tumor Testing IDH1 and IDH2 Mutation Test: Brain Cancer, Leukemia, Cholangiocarcinoma, and Results

IDH1 and IDH2 Mutation Test: Brain Cancer, Leukemia, Cholangiocarcinoma, and Results

By
Vita Library
-
4
Learn how IDH1 and IDH2 mutation testing guides diagnosis and treatment in glioma, AML, and cholangiocarcinoma, including positive, negative, and targeted therapy results.

IDH1 and IDH2 mutation testing looks for cancer-driving changes in isocitrate dehydrogenase enzymes. These mutations produce the abnormal metabolite D-2-hydroxyglutarate, which changes DNA and protein regulation and blocks normal cell maturation. The same genes have different clinical roles across cancers. In diffuse glioma, IDH status is central to diagnosis, grading, prognosis, and treatment planning. In acute myeloid leukemia, an IDH1 or IDH2 mutation can support use of a targeted inhibitor and must be interpreted with the full myeloid genetic profile. In intrahepatic cholangiocarcinoma, an IDH1 mutation may qualify a patient for ivosidenib after prior treatment. Testing can use tumor tissue, bone marrow, blood with leukemia cells, or circulating tumor DNA. A positive result must name the gene and exact hotspot because IDH1 and IDH2 inhibitors are not interchangeable. A negative result may need another method or specimen when tumor content is low or the assay does not cover the relevant variants.

  • IDH status helps define adult diffuse gliomas, and an IDH-mutant tumor is biologically different from IDH-wild-type glioblastoma.
  • IDH1 and IDH2 mutations occur in a meaningful subset of AML and can guide mutation-specific targeted therapy.
  • IDH1 mutations occur in roughly 10% to 20% of intrahepatic cholangiocarcinomas, while they are much less common in extrahepatic bile duct cancers.
  • The exact gene matters: ivosidenib targets mutant IDH1, while enasidenib targets mutant IDH2 in AML.
  • IDH-inhibitor differentiation syndrome can be life-threatening and requires prompt recognition during leukemia treatment.

Table of Contents

What IDH1 and IDH2 mutations do

IDH1 and IDH2 normally help convert isocitrate into alpha-ketoglutarate while producing reducing power for cellular metabolism. IDH1 works mainly in the cytoplasm and peroxisomes, while IDH2 works in mitochondria. Cancer-associated hotspot mutations give the enzymes a new activity: they convert alpha-ketoglutarate into D-2-hydroxyglutarate, often shortened to 2-HG.

High 2-HG interferes with alpha-ketoglutarate-dependent enzymes. The result is abnormal DNA and histone methylation, impaired cellular differentiation, and a state that supports tumor formation. Because the mutation creates an abnormal enzyme activity rather than simply eliminating the protein, it can be targeted with a small-molecule inhibitor.

The most common hotspots differ by gene and tumor:

  • IDH1 R132 is the dominant hotspot in glioma and cholangiocarcinoma and is also seen in AML.
  • IDH2 R140 is common in AML.
  • IDH2 R172 occurs in AML and a smaller portion of gliomas.

IDH mutations are usually somatic. A tumor result generally does not imply inherited cancer risk. Rare constitutional IDH1 or IDH2 mosaic variants cause disorders such as Ollier disease or Maffucci syndrome, but those settings have distinctive skeletal findings and require separate genetics evaluation.

The phrase IDH-mutant must be distinguished from IDH-wild type. Wild type means no reportable mutation was found in the tested regions. It does not mean the tumor lacks every metabolic abnormality, and it does not describe risk without the tumor type.

An IDH mutation can be an early, stable driver in glioma, but its stability varies in other cancers and under treatment pressure. The surrounding molecular context remains important. In AML, IDH can coexist with NPM1, DNMT3A, FLT3, or other mutations. In glioma, ATRX, TP53, and chromosome 1p/19q status help define the tumor class.

IDH testing in brain tumors

IDH testing is fundamental in adult diffuse gliomas. Modern classification integrates histology with molecular features rather than relying only on how cells look under the microscope.

The principal adult diffuse glioma groups include:

  • Astrocytoma, IDH-mutant, usually with ATRX loss and TP53 alteration and without whole-arm 1p/19q codeletion.
  • Oligodendroglioma, IDH-mutant and 1p/19q-codeleted. Both an IDH mutation and complete codeletion are required for this diagnosis.
  • Glioblastoma, IDH-wild type, which has a different biology, age distribution, treatment course, and prognosis.

An older report saying “glioblastoma, IDH-mutant” may be reclassified under current criteria as astrocytoma, IDH-mutant, grade 4. This distinction matters because IDH-mutant grade 4 astrocytoma generally has a better average prognosis than IDH-wild-type glioblastoma, although it remains a serious malignant brain tumor.

How laboratories test gliomas

Immunohistochemistry with an antibody against IDH1 R132H detects the most common glioma mutation. It is fast, inexpensive, and can show mutant cells within the tissue. A positive stain in the correct pattern often establishes the mutation.

A negative R132H stain does not exclude all IDH mutations. Sequencing is recommended when the patient’s age, tumor location, histology, or other markers make a noncanonical IDH1 or IDH2 mutation plausible. This is particularly important in younger adults with a diffuse glioma that lacks typical features of IDH-wild-type glioblastoma.

Next-generation sequencing or targeted sequencing can identify the exact IDH1 or IDH2 variant and assess other diagnostic markers. DNA methylation profiling may help classify difficult tumors. Pathologists combine these results with ATRX, p53, TERT promoter, EGFR, CDKN2A/B, and 1p/19q data.

IDH status influences grade and prognosis but does not replace grade. An IDH-mutant astrocytoma can be grade 2, 3, or 4. Homozygous deletion of CDKN2A/B is sufficient for grade 4 designation in an IDH-mutant astrocytoma even without necrosis or microvascular proliferation.

Treatment implications

Surgery aims to obtain diagnosis and remove as much tumor as safely possible. Age, symptoms, tumor size, residual disease, grade, molecular class, and neurologic function guide whether radiotherapy and chemotherapy are needed immediately.

Vorasidenib is an oral inhibitor of mutant IDH1 and IDH2 that crosses the blood-brain barrier. In the INDIGO trial, it prolonged progression-free survival and delayed the next intervention in selected patients with grade 2 IDH-mutant glioma who had undergone surgery and had not received prior radiation or chemotherapy. Eligibility is narrower than simply having any IDH-mutant brain tumor.

Liver enzyme monitoring is important with vorasidenib. Treatment does not replace imaging, seizure care, rehabilitation, or established radiation and chemotherapy when those are indicated. An IDH result should be reviewed within a complete neuro-oncology plan.

IDH-mutant gliomas often grow over years, but slow growth does not make them harmless. Serial MRI should be compared with the earliest available scan, and subtle expansion on T2/FLAIR sequences can matter even without contrast enhancement. New enhancement, faster growth, worsening seizures, cognitive change, weakness, language difficulty, or increased steroid need can signal progression or transformation.

Magnetic resonance spectroscopy can sometimes detect 2-HG noninvasively, but it is not a universal substitute for tissue diagnosis or validated molecular testing. Technical quality, tumor location, size, and scanner expertise affect performance. Blood 2-HG is not a routine screening test for an IDH-mutant brain tumor.

IDH testing in acute myeloid leukemia

IDH1 or IDH2 mutations occur in roughly 15% to 20% of AML overall, with frequency varying by age, disease subtype, and co-mutations. Testing is part of the initial myeloid molecular panel because the result can guide therapy at diagnosis or relapse.

Bone marrow aspirate is usually preferred, but peripheral blood is acceptable when enough leukemia blasts circulate. A rapid assay may be needed when a targeted inhibitor is being considered. Repeat testing at relapse is useful because the clonal composition can change.

In AML, the prognostic meaning of IDH is not uniform. It depends on the exact gene and codon, NPM1 and FLT3 status, cytogenetics, myelodysplasia-related mutations, treatment intensity, and measurable residual disease. IDH1 or IDH2 does not alone assign the ELN risk group.

The exact codon can also shape biology. IDH2 R172 AML may occur in a different co-mutation pattern from IDH2 R140 disease, and IDH1-mutant AML is not identical to IDH2-mutant AML. These distinctions may influence research analyses, but routine treatment still depends mainly on whether the mutation is susceptible to the selected inhibitor and how the leukemia responds.

When AML is diagnosed after prior chemotherapy or from an antecedent myeloid disorder, IDH should be interpreted with therapy-related and myelodysplasia-related features. A targetable mutation does not cancel adverse-risk genetics. Conversely, an adverse-risk label does not make a targeted inhibitor useless; it informs transplant and consolidation discussions.

IDH mutations often occur in an ancestral clone and can persist during remission. Persistence may represent residual preleukemic hematopoiesis or active leukemia, depending on the variant, level, co-mutations, and clinical setting. Standard NGS positivity after treatment should not automatically be equated with morphologic relapse. Sensitive MRD interpretation requires a validated assay and expertise.

IDH-targeted AML treatment

Ivosidenib inhibits mutant IDH1. It is used in several AML settings, including selected newly diagnosed older or unfit adults, often with azacitidine, and relapsed or refractory IDH1-mutated AML. Olutasidenib is another mutant IDH1 inhibitor used in relapsed or refractory AML in the United States.

Enasidenib inhibits mutant IDH2 and is used for relapsed or refractory IDH2-mutated AML in the United States. It may produce differentiation of leukemia cells rather than rapid cell killing, so blood counts and marrow appearances can change gradually.

Targeted therapy selection depends on prior treatment, fitness, co-mutations, transplant goals, availability, and current approvals. A patient with both FLT3 and IDH alterations may have several options; the hematology team chooses sequence or combinations based on evidence rather than simply targeting every mutation at once. The related FLT3 mutation result can strongly affect the same plan.

An NPM1 mutation test may provide a more standardized molecular MRD marker when present. Flow cytometry, cytogenetics, and marrow morphology remain important alongside molecular testing.

IDH testing in cholangiocarcinoma

IDH1 mutations are found mainly in intrahepatic cholangiocarcinoma, a bile duct cancer arising within the liver. Reported frequencies are often around 10% to 20%. IDH2 mutations are less common, and either gene is uncommon in extrahepatic cholangiocarcinoma and gallbladder cancer.

Broad molecular profiling is recommended in advanced biliary tract cancer because several alterations may guide treatment, including IDH1, FGFR2 fusions, BRAF V600E, HER2 amplification or overexpression, NTRK and RET fusions, mismatch-repair deficiency, and others. A solid-tumor NGS panel is usually more efficient than separate single-gene tests.

Ivosidenib is an established option for adults with previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma in applicable jurisdictions. In the ClarIDHy trial, it delayed progression compared with placebo. The objective response rate was low, but disease stabilization produced meaningful clinical benefit for a subset of patients.

The treatment indication requires a susceptible IDH1 mutation, not merely high 2-HG or an IDH2 alteration. The report should name the exact variant and classify it as activating. An IDH1 VUS should not be assumed to qualify.

Testing can use a biopsy, surgical specimen, or plasma circulating tumor DNA. Tissue provides histology and may detect alterations when blood shedding is low. Plasma can be useful when tissue is limited and can survey multiple metastatic sites. A negative plasma result should be followed by tissue testing when feasible and clinically important.

IDH1 status is not a screening marker and does not diagnose cholangiocarcinoma by itself. Pathology, imaging, and clinical location establish the cancer. IDH can occasionally be detected in other tumors, so the specimen label and diagnosis must be correct.

At progression on an IDH inhibitor, repeat profiling may reveal secondary IDH mutations, isoform switching between IDH1 and IDH2, or alternative pathway changes. Such findings may support a clinical trial, but routine treatment options for resistance remain limited.

In resectable cholangiocarcinoma, surgery remains the main potentially curative treatment, and an IDH1 mutation does not by itself indicate postoperative ivosidenib outside a guideline-supported or research setting. In unresectable disease, first-line therapy is selected from current biliary cancer regimens before later-line mutation-directed treatment. This sequencing prevents a molecular result from being mistaken for a complete treatment plan.

The pathologist should also confirm that the tumor is intrahepatic cholangiocarcinoma rather than a metastasis to the liver from another organ. IDH1 supports but does not prove biliary origin. Clinical imaging, morphology, immunohistochemistry, and the full genomic profile help resolve difficult cases.

Samples, methods, and result interpretation

The appropriate specimen depends on the cancer:

  • resected tumor or biopsy for glioma and cholangiocarcinoma;
  • bone marrow or blast-rich blood for AML;
  • plasma circulating tumor DNA for selected advanced solid tumors;
  • cerebrospinal fluid testing in specialized brain-tumor situations; or
  • archived tissue when a new procedure is not feasible.

Methods include mutation-specific immunohistochemistry, PCR, digital PCR, Sanger sequencing, pyrosequencing, and NGS. Assays should cover IDH1 R132 and IDH2 R140 and R172 at minimum when relevant. A glioma workup must not stop at IDH1 R132H immunohistochemistry when noncanonical mutations remain plausible.

A complete report should include:

  • gene and transcript;
  • DNA and protein notation;
  • specimen and tumor or blast percentage;
  • variant allele fraction;
  • pathogenicity or oncogenicity classification;
  • assay coverage and detection limit;
  • treatment associations for the diagnosed cancer; and
  • whether the test is validated as a companion diagnostic.

Variant allele fraction reflects the proportion of reads carrying the mutation. It is influenced by tumor purity, normal cells, copy number, and clonal structure. A 30% VAF does not mean 30% of the tumor is malignant or that a drug has a 30% chance of working.

A positive result can have three different meanings: it may help define a glioma, provide an actionable AML target, or identify a cholangiocarcinoma treatment option. Those meanings should not be transferred across tumors without evidence.

A negative result can be true or technically limited. Low tumor content, necrosis, decalcification, old tissue, hemodiluted marrow, low plasma tumor fraction, or incomplete hotspot coverage can cause a false negative. If the result conflicts with pathology or expected biology, another block, specimen, or method may be appropriate.

A VUS is not equivalent to a hotspot mutation. The laboratory may find a rare IDH1 or IDH2 change outside the catalytic hotspot. Treatment should not be selected without evidence that it produces 2-HG and matches an approved or trial-defined alteration. The variant classification and the therapy evidence tier should be reviewed separately.

Targeted treatment, safety, and resistance

IDH inhibitors lower 2-HG and allow cells to resume aspects of normal differentiation. Their effects and toxicities differ between solid tumors and leukemia.

Differentiation syndrome

IDH-inhibitor differentiation syndrome is a serious AML complication. As leukemia cells mature, inflammatory signals can cause fever, shortness of breath, low blood pressure, rapid weight gain, swelling, pleural or pericardial fluid, kidney dysfunction, and lung infiltrates. It can occur days to months after treatment begins.

Patients should contact the treatment team immediately for these symptoms. Management often includes corticosteroids, close monitoring, diuretics or other supportive care, and temporary drug interruption in severe cases. Leukocytosis may require hydroxyurea. Differentiation syndrome can occur with or without a rising white-cell count.

Other adverse effects

Ivosidenib can prolong the QT interval and interact with drugs that affect CYP enzymes or cardiac rhythm. Electrocardiograms, electrolytes, liver tests, and medication review may be required. Enasidenib can cause elevated indirect bilirubin through inhibition of bilirubin metabolism without true liver injury, but other causes must still be assessed. Cytopenias, nausea, fatigue, diarrhea, and appetite changes may occur.

Vorasidenib can cause substantial liver-enzyme elevation. Baseline and scheduled liver testing are required, with dose interruption or reduction when indicated. Patients should report jaundice, dark urine, severe fatigue, or right-upper-abdominal pain.

In cholangiocarcinoma, ivosidenib is generally taken continuously until progression or unacceptable toxicity. QT monitoring and drug interactions remain relevant. Treatment response is assessed through imaging and clinical status rather than 2-HG level alone.

Resistance

Resistance mechanisms include secondary mutations at the IDH dimer interface, switching from mutant IDH1 to mutant IDH2 or vice versa, persistence of other driver clones, and pathway changes that reduce dependence on 2-HG. AML may relapse without the original IDH mutation, while another clone becomes dominant.

Repeat molecular profiling at progression can clarify whether the target remains present. A liquid biopsy or new tissue sample may identify resistance, but a new finding does not guarantee an available drug. Clinical trials may study next-generation inhibitors, combinations, or strategies targeting epigenetic dependence.

Stopping an IDH inhibitor solely because the mutation remains detectable can be inappropriate. Conversely, continuing it after clear clinical progression may provide no benefit unless part of a deliberate combination or trial plan. Imaging, marrow findings, counts, symptoms, and mutation results must be interpreted together.

Questions and next steps after testing

Bring the complete pathology or molecular report to the results visit. Ask:

  1. Is the alteration in IDH1 or IDH2, and what exact codon is affected?
  2. Does the result define my tumor type, guide treatment, or both?
  3. Was the specimen adequate, and what was the assay’s detection limit?
  4. For glioma, were 1p/19q, ATRX, TP53, CDKN2A/B, and other required markers assessed?
  5. For AML, how do NPM1, FLT3, chromosomes, and MRD change the meaning?
  6. For cholangiocarcinoma, was broad profiling completed for other actionable alterations?
  7. Which IDH inhibitor fits this gene, cancer type, and treatment setting?
  8. What symptoms of differentiation syndrome, liver injury, or QT prolongation need urgent reporting?

A positive result should lead to a tumor-specific plan. In glioma, that may mean integrated diagnosis, risk assessment, surveillance, surgery, radiation, chemotherapy, or vorasidenib. In AML, it may affect induction or lower-intensity therapy, relapse treatment, MRD assessment, and transplant strategy. In cholangiocarcinoma, it may provide a later-line targeted option.

A negative result should prompt review of coverage and specimen quality rather than automatic retesting. When testing was comprehensive and adequate, attention should move to other biomarkers and standard treatment.

Keep all reports labeled by date and specimen. A bone marrow result at AML diagnosis, a resection result from a glioma, and a plasma result from metastatic cholangiocarcinoma answer different questions. Clear records prevent a mutation from being mistakenly applied to the wrong disease or time point.

IDH testing is highly useful because one metabolic pathway links several cancers, but precision depends on context. The exact gene, mutation, tumor, stage, and treatment history determine whether the result is diagnostic, prognostic, actionable, or simply descriptive.

References

Disclaimer

This article is educational and does not replace interpretation by neuro-oncology, hematology, pathology, or gastrointestinal oncology specialists. IDH-directed treatment depends on the exact mutation, cancer type, disease setting, prior treatment, and current approvals. Fever, breathing difficulty, rapid swelling, jaundice, fainting, or other severe symptoms during an IDH inhibitor require urgent medical contact.

RELATED ARTICLESMORE FROM AUTHOR